Cabaletta Bio Inc
NASDAQ:CABA
Cabaletta Bio Inc
NASDAQ:CABA
Price:
3.39
USD
4.31%
Market Closed
Market Cap:
$326.4m
Relative Value
There is not enough data to reliably calculate the relative value of CABA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CABA
Relative Value
Base Case
Not Available
Multiples Across Competitors
CABA Competitors Multiples
Cabaletta Bio Inc Competitors
Cabaletta Bio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
326.3m USD | 0 | -1.9 | -1.1 | -1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
417.5B USD | 6.8 | 99.9 | 16.3 | 22.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.7B USD | 5.6 | 26.5 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 13.9 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.1B AUD | 3.2 | 35 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.3B EUR | 11.2 | 35.8 | 39 | 39.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
